A detailed history of New Edge Advisors, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 300 shares of NTLA stock, worth $3,615. This represents 0.0% of its overall portfolio holdings.

Number of Shares
300
Holding current value
$3,615
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $5,916 - $8,208
300 New
300 $6,000
Q1 2024

May 14, 2024

BUY
$23.82 - $32.8 $952 - $1,312
40 New
40 $1,000
Q3 2023

Nov 14, 2023

SELL
$31.62 - $45.78 $10,529 - $15,244
-333 Reduced 99.11%
3 $0
Q2 2023

Aug 14, 2023

SELL
$34.58 - $46.03 $6,328 - $8,423
-183 Reduced 35.26%
336 $13,000
Q1 2023

May 12, 2023

SELL
$33.3 - $44.82 $24,142 - $32,494
-725 Reduced 58.28%
519 $19,000
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $41,313 - $77,986
1,244 New
1,244 $43,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $916M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.